A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.
Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials.
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Erica S
ES
Tsang
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Marie
M
de Haan
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Bernhard J
BJ
Eigl
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000150:complications / Q000188:drug therapy*; D006435:Renal Dialysis
D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide
Prostate cancer; dialysis; enzalutamide